Key Functional Cell Identity (KFCI) identifies super-donor cells before clinical trials start, accelerating the development and production of cell therapy. KFCI reduces costs by up to 90% via filtering out ineffective samples and creates an allogenic stem-cell bank for over 40 different medical conditions, including diabetes and myocardial infarction. This platform is capable of mass-producing high-quality cells to generate 100,000-500,000 doses of therapeutic products from one donor. It has been licensed to biotechnology companies such as Reliance Medical Technology Corporation for clinical trials. It is a silver-winning technology in the health, medicine, and biotech category at the Edison Awards.